Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
Orthopaedic Research Center, C. Wayne McIlwraith Translational Medicine Institute, Colorado State University, Fort Collins, Colorado, USA.
Vet Surg. 2022 May;51(4):557-567. doi: 10.1111/vsu.13805. Epub 2022 Apr 5.
To evaluate the use of mesenchymal stem cells (MSCs), autologous conditioned serum (ACS), platelet-rich plasma (PRP), and autologous protein solution (APS) for the treatment of equine musculoskeletal disease by diplomates of the American College of Veterinary Surgery (ACVS), and American College of Veterinary Sports Medicine and Rehabilitation (ACVSMR).
Cross-sectional study.
Diplomates (n = 423).
An email link was sent to ACVS and ACVMR diplomates. A survey contained 59 questions regarding demographics, as well as indications, frequency, adverse effects, and limitations of use. Responses were analyzed using Fisher's exact test.
One hundred and fifty four surveys were analyzed. Years in practice and type of practice were not associated with biologic therapy use. PRP was the most used therapy (120/137; 87.5%). PRP and MSCs were most often administered intralesionally while ACS and APS were most often administered intra-articularly. ACS (50/104; 48.1%) treatment was repeated commonly within 2 weeks of initial injection. MSCs (39/90; 43.3%) and PRP (38/100; 38%) were commonly repeated 1-2 months after initial injection and APS was typically repeated >4 months after initial injection (21/53; 39.6%). Local inflammation and expense were the most common adverse effect and limitation of use.
Diplomates most commonly utilized PRP and MSC intralesionally for soft-tissue injuries, and ACS and ACP intra-articularly for joint injury. Protocols for repeated administration varied widely. Local inflammation was a clinical concern with the use of biologics.
Biologic therapies are used commonly by ACVS and ACVSMR diplomates for soft tissue and joint disease.
评估美国兽医外科学院（ACVS）和美国兽医运动医学与康复学院（ACVSMR）的兽医外科医师委员会成员使用间充质干细胞（MSCs）、自体条件血清（ACS）、富血小板血浆（PRP）和自体蛋白溶液（APS）治疗马属动物肌肉骨骼疾病的情况。
横断面研究。
委员会成员（n=423）。
向 ACVS 和 ACVSMR 的委员会成员发送电子邮件链接。调查包含 59 个问题，涉及人口统计学、适应证、使用频率、不良反应和使用限制。使用 Fisher 确切检验分析结果。
分析了 154 份调查。从业年限和执业类型与生物治疗的使用无关。PRP 是使用最多的治疗方法（120/137；87.5%）。PRP 和 MSCs 最常经皮内注射给药，而 ACS 和 APS 最常经关节内注射给药。ACS（50/104；48.1%）治疗在初次注射后 2 周内经常重复。MSCs（39/90；43.3%）和 PRP（38/100；38%）在初次注射后 1-2 个月内经常重复，而 APS 通常在初次注射后>4 个月内重复（21/53；39.6%）。局部炎症和费用是最常见的不良反应和使用限制。
委员会成员最常经皮内注射 PRP 和 MSCs 治疗软组织损伤，经关节内注射 ACS 和 ACP 治疗关节损伤。重复给药方案差异很大。局部炎症是生物制剂使用的临床关注点。
ACVS 和 ACVSMR 的兽医外科医师委员会成员普遍使用生物疗法治疗软组织和关节疾病。
